SavedAdd your journal

Journals / GORM:Gynecology Obstetrics & Reproductive Medicine / 2019 / Cilt: 25 - Sayı: 2

An Intelligent Prenatal Screening System for the Prediction of Trisomy-21 Using Triple Test Variables: The Hacettepe System

Doruk Cevdi KATLAN
Atakan TANAÇAN
Gökçen ÖRGÜL
MEHMET KEMAL LEBLEBİCİOĞLU
Mehmet Sinan BEKSAÇ
Pages
67–69
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: We have developed an intelligent system using the backpropagation learning algorithm (using triple test variables) to predict trisomy 21.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: To introduce an intelligent prenatal screening system, using triple test variables.
📊
Key Findings & Data:Unconjugated estriol (E3), beta-human chori- onic gonadotropin, and α-feto protein with gestational week and maternal age (triple test) were used as input variables in the training and testing.
💡
Conclusion & Impact:CONCLUSION: We have developed an intelligent system using the backpropagation learning algorithm (using triple test variables) to predict trisomy 21.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

OBJECTIVE: To introduce an intelligent prenatal screening system, using triple test variables. STUDY DESIGN: In this study, we have used a backpropagation learning algorithm (a supervised arti- ficial neural network) to develop an intelligent antenatal screening system (heretofore referred as Hacettepe System). Triple test variables were used as input variables, while “Down syndrome” and “non- Down syndrome” fetuses were the output of the algorithm. Unconjugated estriol (E3), beta-human chori- onic gonadotropin, and α-feto protein with gestational week and maternal age (triple test) were used as input variables in the training and testing. Multiples of median values of the E3, α-feto protein, and beta- human chorionic gonadotropin were used in this study. The testing group of Hacettepe system consisted of 97 patients who were found to be high-risk (>1/250) during the routine antenatal screening (triple test) and underwent amniocentesis for fetal karyotyping. RESULTS: Amniocentesis was performed in 97 pregnancies with “high-risk” triple test results (>1/250). Fetal karyotyping revealed trisomy 21 in about 9.3% (9/97) of the pregnancies. Our algorithm (Hacettepe System) detected 77.8% (7/9) of Down syndrome cases. Moreover, all of the normal fetal karyotypes were assigned as normal in the Hacettepe System. CONCLUSION: We have developed an intelligent system using the backpropagation learning algorithm (using triple test variables) to predict trisomy 21.

🔖

Cite This Article

KATLAN, D. C., TANAÇAN, A., ÖRGÜL, G., LEBLEBİCİOĞLU, M. K., BEKSAÇ, M. S. (2019). An Intelligent Prenatal Screening System for the Prediction of Trisomy-21 Using Triple Test Variables: The Hacettepe System. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 25 - Sayı: 2, 67–69. https://ajindex.com/articles/160459

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Driscoll DA, Gross S. Prenatal screening for aneuploidy. N Engl J Med. 2009;360(24):2556-62. American College of Obstetricians and Gynecologists. Practice Bulletin No. 27: Clinical Management Guidelines for Obstetrician-Gynecologists. Prenatal diagnosis of fetal chromosomal abnormalities. Obstet Gynecol. 2001;97(5 Pt 1):suppl 1-12.
  2. Norton ME, Jelliffe-Pawlowski LL, Currier RJ. Chromosome abnormalities detected by current prenatal screening and noninvasive prenatal testing. Obstet Gynecol. 2014;124(5):979-86.
  3. Gokcen O, Mehmet D, Emine A, Mehmet A, Sinan BM. An overview of prenatal screening/diagnosis programs for Down syndrome in Turkey. Int J Hum Genet. 2016;16 (1,2):29-34.
  4. Okem ZG, Orgul G, Kasnakoglu BT, Cakar M, Beksac MS. Economic analysis of prenatal screening strategies for Down syndrome in singleton pregnancies in Turkey. Eur J Obstet Gynecol Reprod Biol. 2017;219:40-4.
  5. Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkinen A, Canick JA, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med. 1992;327(9):588-93.
  6. Beksac M, Beksac MS, Tipi VB, Duru HA, Karakas MU, Cakar AN. An artificial intelligent diagnostic system on differential recognition of hematopoietic cells from mi- croscopic images. Cytometry. 1997;30(3):145-50.
  7. Beksac MS, Basaran F, Eskiizmirliler S, Erkmen AM, Yorukan S. A computerized diagnostic system for the in- terpretation of umbilical artery blood flow velocity wave- forms. Eur J Obstet Gynecol Reprod Biol. 1996;64(1):37- 42. Beksac MS, Tanacan A, Bacak HO, Leblebicioglu K. Computerized prediction system for the route of delivery (vaginal birth versus cesarean section). J Perinat Med. 2018;46(8):881-4.
  8. Beksac MS, Durak B, Ozkan O, Cakar AN, Balci S, Karakas U, et al. An artificial intelligent diagnostic system with neural networks to determine genetical disorders and fetal health by using maternal serum markers. Eur J Obstet Gynecol Reprod Biol. 1995;59(2):131-6.
  9. Boyd PA, Devigan C, Khoshnood B, Loane M, Garne E, Dolk H, et al. Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down’s syndrome. BJOG 2008;115(6): 689-96. Dondorp W, de Wert G, Bombard Y, Bianchi DW, Bergmann C, Borry P, et al. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible in- novation in prenatal screening. Eur J Hum Genet. 2015;23(11):1438-50.
  10. Gregg AR, Skotko